Steven J. Padula

机构：Boehringer Ingelheim (Germany)

发表论文 51 篇 · 总被引 4440 次 · h-index 25

代表论文

• An antibody to lymphotoxin and tumor necrosis factor prevents transfer of experimental allergic encephalomyelitis. (1990 · The Journal of Experimental Medicine · 被引 694)
• Risankizumab versus Ustekinumab for Moderate-to-Severe Plaque Psoriasis (2017 · New England Journal of Medicine · 被引 516)
• The Nuclear Receptor PPARγ and Immunoregulation: PPARγ Mediates Inhibition of Helper T Cell Responses (2000 · The Journal of Immunology · 被引 466)
• Induction therapy with the selective interleukin-23 inhibitor risankizumab in patients with moderate-to-severe Crohn's disease: a randomised, double-blind, placebo-controlled phase 2 study (2017 · The Lancet · 被引 454)
• Risankizumab, an IL-23 inhibitor, for ankylosing spondylitis: results of a randomised, double-blind, placebo-controlled, proof-of-concept, dose-finding phase 2 study (2018 · Annals of the Rheumatic Diseases · 被引 384)
• Inhibition of the Interleukin-36 Pathway for the Treatment of Generalized Pustular Psoriasis (2019 · New England Journal of Medicine · 被引 294)